Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. on March 9, 2016, covering events occurring on March 7, 2016. The filing addresses a change in the Company's executive leadership structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Executive Appointment: On March 7, 2016, Jerome D. Jabbour was appointed as President of the Company.
- Role Transition: Mr. Jabbour previously served as Executive Vice President, Chief Business Officer, General Counsel, and Secretary from October 2013 until March 2016.
- CEO Continuity: Roelof Rongen continues to serve as the Company's Chief Executive Officer.
Guidance, Outlook, and Management Commentary
The filing states that the terms of Mr. Jabbour's employment agreement remain unchanged. Detailed biographical information and the employment agreement are referenced as previously disclosed in the Company's proxy statement filed on September 15, 2015, and as Exhibit 10.12 to Amendment No. 1 to the Form S-1 Registration Statement filed on February 7, 2014. No new financial guidance, risks, or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the specific terms of Jerome D. Jabbour's employment agreement via the referenced Exhibit 10.12 in the February 7, 2014 Form S-1 Amendment.
- Review the September 15, 2015 proxy statement for Mr. Jabbour's full biography and prior compensation history.
- Confirm the current status of the Company's cash position and burn rate, as this 8-K does not address liquidity.